Insights into Company

Illumina ↗

Part of Illumina.

2000 📍 Bangalore, Karnataka, United States Active NASDAQ ILMN CIN U51100KA2018FTC218784 Pharmaceuticals & Healthcare
Search companies

Key Metrics of Illumina

Revenue$4.5B▼ 1.7% YoYFY 2023
Operating income−$1.1B▲ 74.4% YoY
Net profit−$1.2B▲ 73.6% YoY
Shareholders' equity$5.7B
Market cap$40.7BILMN · $269.42
Competitors10identified
Open jobs1

About Illumina

Part of Illumina.

Sectors

Pharmaceuticals & HealthcareBiotechnology & Vaccines

Company details

Website
illumina.com
Founded
2000
Registered office
3rd Floor, M2 Block, Manyata Embassy Business Park, Venkateshapura, Bangalore, Bangalore North, Karnataka, Bangalore, In-ka, 560045
Listed
Nasdaq: ILMN (since 2000)

Operational Areas of Illumina

Pharmaceuticals & Healthcare›Biotechnology & Vaccines

Company summary

Entity details

CINU51100KA2018FTC218784
LEI code335800MIZ5EA4CZUDG10
State codeKA
PIN code560045
Current legal nameILLUMINA
Classification—
Listing statusUnlisted
Registration no.218784
Company age—
PAN—
CountryUnited States
CityBangalore
StateKarnataka
Current statusActive
Date of incorporation—
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—

Compliance

Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026

Industry classification

NIC code51100
Description of main activityWholesale trade and commission trade
Description of business activityWholesale trade and commission trade
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines

US market & SEC filings

ILMN · Nasdaq  ·  SEC CIK 0001110803

Last price · 27 Oct 2026 $269.42 +0.01%
Market cap$40.7B
P/E—On FY 2023 diluted EPS
Volume1,262,922
SectorHealth CareMedical Specialities
Country · IPOUnited StatesListed 2000

ILMN share price

Premium

Annual results (SEC EDGAR)

Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026 Statutory due date · 3 days left
MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 33 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Registered office and contact

Registered office3RD FLOOR, M2 BLOCK, MANYATA EMBASSY BUSINESS PARK, VENKATESHAPURA, BANGALORE, BANGALORE NORTH, KARNATAKA, BANGALORE, IN-KA, 560045
GSTIN—
Email—
Websitehttps://www.illumina.com
Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Illumina

Competitors10identified
Locations1most in United States

Top competitors by location

CompanyDescriptionDomainFoundedLocation
Vertex Pharmaceuticals Part of Vertex Pharmaceuticals. vrtx.com 1991 United States
Moderna Biotechnology & Vaccines · Pharmaceuticals & Healthcare modernatx.com 2018 United States
Becton Dickinson Biotechnology & Vaccines · Pharmaceuticals & Healthcare bd.com — United States
Guardant Health Biotechnology & Vaccines · Pharmaceuticals & Healthcare guardanthealth.com 2018 United States
Revvity Inc. Biotechnology & Vaccines · Pharmaceuticals & Healthcare revvity.com — United States
Exelixis Biotechnology & Vaccines · Pharmaceuticals & Healthcare exelixis.com 2000 United States
Neurocrine Biosciences Biotechnology & Vaccines · Pharmaceuticals & Healthcare neurocrine.com 1996 United States
BioMarin Pharmaceutical Biotechnology & Vaccines · Pharmaceuticals & Healthcare biomarin.com 1999 United States
Bio-Rad Laboratories Biotechnology & Vaccines · Pharmaceuticals & Healthcare bio-rad.com 1980 United States
10X Genomics Biotechnology & Vaccines · Pharmaceuticals & Healthcare 10xgenomics.com 2019 United States

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Group companies

Part of Illumina

Business activities and related parties

biotechnology

Filings

No filings on record yet.